title: Launch of Breakthrough Therapies Will Reshape Renal Cell Carcinoma Market.
abstract: Tyrosine kinase inhibitors (TKIs) are leading systemic therapies for the treatment of renal cell carcinoma. However, programmed death-1 inhibitors, promising new agents in development, may surpass TKIs as the standard of care in the future.
authors: Chris
authors: C
authors: Fellner